Astegolimab: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 264 patientsc19early.org

Astegolimab for COVID-19

Serious outcome risk
Astegolimab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−31%
Mortality (1)−31%
RCTs (1)−31%
Late (1)−31%
00.511.5+
← Astegolimab
reduces riskIncreased
risk →
c19early.org
October 2026

Astegolimab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−31%1.31 · 0.69–2.33death19/13015/134COVASTIL
Late treatment−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.41
All studies−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4100.511.52+
Rotate screen for more detailsIncrease width for more details
← Astegolimab
reduces riskAstegolimab
increases risk →
c19early.org
October 2026

Astegolimab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Waters (DB RCT)−31%1.31 · 0.69–2.3319/13015/134COVASTIL
Late treatment−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.41
All studies−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4100.511.52+
Rotate screen for more detailsIncrease width for more details
← Astegolimab
reduces riskAstegolimab
increases risk →
c19early.org
October 2026

Astegolimab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−31%1.31 · 0.69–2.33death19/13015/134COVASTIL
Late treatment−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.41
All studies−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4100.511.52+
Rotate screen for more detailsIncrease width for more details
← Astegolimab
reduces riskAstegolimab
increases risk →
c19early.org
October 2026

Astegolimab COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)1%0.99 · 0.74–1.33no recov.130 (n)134 (n)COVASTIL
Late treatment1%0.99 · 0.74–1.33130 (n)134 (n)1% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.95
All studies1%0.99 · 0.74–1.33130 (n)134 (n)1% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.9500.511.52+
Rotate screen for more detailsIncrease width for more details
← Astegolimab
reduces riskAstegolimab
increases risk →
c19early.org
October 2026

Astegolimab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−31%1.31 · 0.69–2.33death19/13015/134COVASTIL
Late treatment−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.41
All studies−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4100.511.52+
Rotate screen for more detailsIncrease width for more details
← Astegolimab
reduces riskAstegolimab
increases risk →
c19early.org
October 2026

Astegolimab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Waters (DB RCT)−31%1.31 · 0.69–2.3319/13015/134COVASTIL
Late treatment−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.41
All studies−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4100.511.52+
Rotate screen for more detailsIncrease width for more details
← Astegolimab
reduces riskAstegolimab
increases risk →
c19early.org
October 2026

Astegolimab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Waters (DB RCT)−31%1.31 · 0.69–2.33death19/13015/134COVASTIL
Late treatment−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.41
All studies−31%1.31 · 0.69–2.4619/13015/13431% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4100.511.52+
Rotate screen for more detailsIncrease width for more details
← Astegolimab
reduces riskAstegolimab
increases risk →